A Phase 3 interventional study of B/F/TAF and F/TAF in HIV-1-infection, sponsored by Gilead Sciences. Completed at 94 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-11.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the efficacy of switching from a regimen of either dolutegravir (DTG) and emtricitabine /tenofovir alafenamide (F/TAF) or DTG and emtricitabine/tenofovir disoproxil fumarate (F/TDF) to a fixed dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus DTG+F/TAF in virologically suppressed HIV-1 infected adults with or without antiretroviral (ARV) resistance.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Currently receiving an ARV regimen of DTG+F/TAF or DTG+F/TDF for the following minimum time periods:
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination (FDC) tablet + dolutegravir (DTG) placebo tablet + emtricitabine/tenofovir alafenamide (F/TAF) placebo tablet administered without regard to food for at least 48 weeks.
Drug: B/F/TAF · Drug: DTG Placebo · Drug: F/TAF Placebo
DTG 50 mg tablet + F/TAF FDC tablet + B/F/TAF placebo tablet administered without regard to food for at least 48 weeks.
Drug: F/TAF · Drug: DTG · Drug: B/F/TAF Placebo
Participants who received B/F/TAF in double-blind phase and from a country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.
Drug: B/F/TAF
Participants who received DTG + F/TAF in double-blind phase and from a country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.
Drug: B/F/TAF
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
50/200/25 mg FDC tablet(s) administered orally once daily
Also known as: GS-9883/F/TAF, Biktarvy®
Drug pages: Emtricitabine · Tenofovir alafenamide
200/25 mg FDC tablet(s) administered orally once daily
Also known as: Descovy®
50 mg tablet(s) administered orally once daily
Also known as: Tivicay®
Tablet(s) administered orally once daily
Tablet(s) administered orally once daily
Tablet(s) administered orally once daily
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Change From Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline; Week 48
Participants were enrolled at study sites in North America and Europe. The first participant was screened on 12 June 2017. The last study visit occurred on 10 Feb 2021.
| Milestone | B/F/TAF | DTG + F/TAF | B/F/TAF From B/F/TAF | B/F/TAF From DTG + F/TAF |
|---|---|---|---|---|
| Started | 284 | 283 | 0 | 0 |
| Safety analysis set | 284 | 281 | 0 | 0 |
| Completed | 263 | 253 | 0 | 0 |
| Not completed | 21 | 30 | 0 | 0 |
| Withdrew: Withdrew consent | 10 | 16 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 3 | 0 | 0 |
| Withdrew: Adverse event | 3 | 3 | 0 | 0 |
| Withdrew: Investigator's discretion | 1 | 3 | 0 | 0 |
| Withdrew: Death | 2 | 1 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Randomized but not treated | 0 | 2 | 0 | 0 |
| Milestone | B/F/TAF | DTG + F/TAF | B/F/TAF From B/F/TAF | B/F/TAF From DTG + F/TAF |
|---|---|---|---|---|
| Started | 0 | 0 | 125 | 116 |
| Completed | 0 | 0 | 121 | 113 |
| Not completed | 0 | 0 | 4 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 3 | 1 |
| Withdrew: Withdrew consent | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF | DTG + F/TAF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm | 0.4 | 1.1 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF | DTG + F/TAF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm | 93.3 | 91.1 |
| cells/µL | B/F/TAF | DTG + F/TAF |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 48 | 18 ± 179.1 | 36 ± 152.6 |
Collected over Adverse Events: First dose date up to last dose date [maximum: 84.9 weeks (Blinded Phase), 179.6 weeks (Open Label Phase) plus 30 days All-Cause Mortality: Randomization/Enrollment up to 187.7 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-Blind Treatment Phase B/F/TAF | 3/284 (1.1%) | 36/284 (12.7%) | 181/284 (63.7%) |
| Double-Blind Treatment Phase DTG + F/TAF | 2/283 (0.7%) | 27/281 (9.6%) | 170/281 (60.5%) |
| Open-label Extension Phase B/F/TAF From B/F/TAF | 0/125 (0%) | 12/125 (9.6%) | 30/125 (24%) |
| Open-label Extension Phase B/F/TAF From DTG + F/TAF | 0/117 (0%) | 11/116 (9.5%) | 33/116 (28.4%) |
| Event | Double-Blind Treatment Phase B/F/TAF | Double-Blind Treatment Phase DTG + F/TAF | Open-label Extension Phase B/F/TAF From B/F/TAF | Open-label Extension Phase B/F/TAF From DTG + F/TAF |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/284 | 2/281 | 0/125 | 2/116 |
| Acute myocardial infarctionCardiac disorders | 0/284 | 0/281 | 2/125 | 0/116 |
| Lymphocytic infiltrationBlood and lymphatic system disorders | 0/284 | 0/281 | 0/125 | 1/116 |
| Abdominal painGastrointestinal disorders | 0/284 | 1/281 | 0/125 | 1/116 |
| Chest painGeneral disorders | 1/284 | 0/281 | 1/125 | 1/116 |
| Non-cardiac chest painGeneral disorders | 0/284 | 0/281 | 0/125 | 1/116 |
| Cholangitis acuteHepatobiliary disorders | 0/284 | 0/281 | 0/125 | 1/116 |
| Anti-neutrophil cytoplasmic antibody positive vasculitisImmune system disorders | 0/284 | 0/281 | 0/125 | 1/116 |
| Colonic abscessInfections and infestations | 0/284 | 0/281 | 0/125 | 1/116 |
| EpididymitisInfections and infestations | 0/284 | 0/281 | 0/125 | 1/116 |
| Event | Double-Blind Treatment Phase B/F/TAF | Double-Blind Treatment Phase DTG + F/TAF | Open-label Extension Phase B/F/TAF From B/F/TAF | Open-label Extension Phase B/F/TAF From DTG + F/TAF |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 44/284 | 32/281 | 3/125 | 1/116 |
| Upper respiratory tract infectionInfections and infestations | 33/284 | 40/281 | 9/125 | 10/116 |
| DiarrhoeaGastrointestinal disorders | 26/284 | 35/281 | 4/125 | 7/116 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 24/284 | 21/281 | 4/125 | 4/116 |
| HeadacheNervous system disorders | 16/284 | 23/281 | 1/125 | 4/116 |
| FatigueGeneral disorders | 22/284 | 9/281 | 1/125 | 7/116 |
| Back painMusculoskeletal and connective tissue disorders | 20/284 | 15/281 | 2/125 | 3/116 |
| InfluenzaInfections and infestations | 19/284 | 17/281 | 2/125 | 1/116 |
| InsomniaPsychiatric disorders | 19/284 | 14/281 | 1/125 | 3/116 |
| BronchitisInfections and infestations | 18/284 | 14/281 | 4/125 | 5/116 |
The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug.
| Age, Continuous(years) | B/F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| Mean | 50 ± 11.3 | 49 ± 11.3 | 50 ± 11.3 |
| Sex: Female, Male(Participants) | B/F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| Female | 39 | 41 | 80 |
| Male | 245 | 240 | 485 |
| Race/Ethnicity, Customized(Participants) | B/F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 1 | 1 |
| Race — Asian | 3 | 3 | 6 |
| Race — Black | 68 | 61 | 129 |
| Race — Native Hawaiian or Pacific Islander | 2 | 1 | 3 |
| Race — White | 200 | 199 | 399 |
| Race — Other | 9 | 13 | 22 |
| Race — Not Permitted | 2 | 3 | 5 |
| Race/Ethnicity, Customized(Participants) | B/F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 61 | 49 | 110 |
| Ethnicity — Not Hispanic or Latino | 220 | 229 | 449 |
| Ethnicity — Not Permitted | 3 | 3 | 6 |
| Region of Enrollment(Participants) | B/F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| Canada | 24 | 25 | 49 |
| Austria | 2 | 1 | 3 |
| United States | 197 | 202 | 399 |
| France | 12 | 14 | 26 |
| Germany | 30 | 26 | 56 |
| Puerto Rico | 19 | 13 | 32 |
| HIV-1 RNA Category(Participants) | B/F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| < 50 copies/mL | 276 | 275 | 551 |
| ≥ 50 copies/mL | 8 | 6 | 14 |
| CD4 Cell Count(Cells/μL) | B/F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| Mean | 714 ± 309.1 | 658 ± 294.7 | 686 ± 303.1 |
| CD4 Cell Count Category(Participants) | B/F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| < 50 Cells/ μL | 0 | 1 | 1 |
| ≥ 50 to < 200 Cells/μL | 6 | 6 | 12 |
| ≥ 200 to < 350 Cells/μL | 18 | 34 | 52 |
| ≥ 350 to < 500 Cells/μL | 53 | 44 | 97 |
| ≥ 500 Cells/ μL | 207 | 196 | 403 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Jun 2017 to primary completion in Dec 2018, 17 months.
Results were first posted in Nov 2019, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide